A Phase 2 interventional study of AR882 75 mg and XOI Low Dose in Gout, Gouty Arthritis and Hyperuricemia, sponsored by Arthrosi Therapeutics. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.
This study's planned enrollment of 15 is below the median of 140 across 35 interventional studies indexed under Arthritis, Gouty.
Browse Arthritis, Gouty studies →Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.
Compared within Arthritis, Gouty, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gout. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AR882 75 mg plus XOI low dose taken once daily starting on Day 1 for 2 weeks then titrate up to AR882 75 mg plus XOI high dose taken once daily for duration of 6-month treatment period.
Drug: AR882 75 mg · Drug: XOI Low Dose · Drug: XOI High Dose
Solid Oral Capsule
Solid Oral Tablet
Solid Oral Tablet
Serum urate (uric acid) (sUA) level < 6 mg/dL at month 6
Proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL at month 6
Time frame: 24 weeks
Change in tophus burden by month 6
Change in tophus burden by measurement of targeted tophi area at Month 6
Time frame: 24 weeks
Incidence of Adverse Events
Treatment Emergent Adverse Events and Serious Adverse Event incidence
Time frame: 56 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AR882